Gilead to launch Phase 3 trial of oral α4β7 inhibitor after promising Phase 2 ulcerative colitis results

Gilead Sciences announced plans to begin Phase 3 trials next year for its oral α4β7 integrin inhibitor aimed at treating ulcerative colitis.

The move follows a Phase 2 dose‑finding study that reported higher remission rates than the existing intravenous therapy Entyvio.

If the late‑stage trials confirm the early efficacy, the oral drug could offer a more convenient option for patients and may shift the competitive landscape of ulcerative colitis treatments.